According to Dr. Patrick Lu, CEO of Sirnaomics, Dr. Lebel's ...
According to Dr. Patrick Lu, CEO of Sirnaomics, Dr. Lebel's promotion will enrich Sirnaomics' ability to advance its clinical-stage and pre-clinical RNAi-based treatments. Dr. Lebel himself expressed commitment to lead Sirnaomics' RNAi pipeline through clinical development to the commercial stage.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more